(Q45749970)

English

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure

scientific article published on 4 March 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

0 references

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Merete Lund Hetland

object named as

Merete L Hetland

3

0 references

author name string

Sophine B Krintel

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

Veit Peter Grunert

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

Julia S Johansen

4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

Matthias Rothfuss

5

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

Giuseppe Palermo

6

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

Laurent Essioux

7

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

Ursula Klause

8

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

52

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

7

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

1245-1253

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

DANBIO--powerful research database and electronic patient record

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Dealing with immunogenicity of biologicals: assessment and clinical relevance

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET017

21 January 2018

Identifiers

10.1093/RHEUMATOLOGY/KET017

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23459699

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45749970&oldid=2080948916"